{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:27:40Z","timestamp":1793291260587,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the utility of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in monitoring the response to Ra-223 therapy in patients with castration-resistant prostate cancer (CRPC) and bone metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>This retrospective study included 15 patients with CRPC and bone metastases. DWIBS scans were performed at baseline and after three cycles of Ra-223 therapy. Quantitative analysis of tumor total diffusion volume (tDV) categorized patients as stable disease (DWIBS-SD), partial response (DWIBS-PR), or progressive disease (DWIBS-PD). Kaplan\u2013Meier analysis and log-rank tests were used to assess the correlation between DWIBS findings and survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 15 patients (median age 72\u00a0years\u2009\u00b1\u20097.3), 7 (47%) were classified as DWIBS-SD, 3 (20%) as DWIBS-PR, and 5 (33%) as DWIBS-PD. DWIBS-PD group had significantly shorter survival than the DWIBS-non-PD group (<jats:italic>P<\/jats:italic>\u2009=\u20090.004). Despite no significant differences in age, alkaline phosphatase, prostate-specific antigen or bone metastasis volume, DWIBS-PD group had a significantly higher proportion of patients with Eastern Cooperative Oncology Group performance status score of 2 before the treatment compared to DWIBS-non-PD group (<jats:italic>P<\/jats:italic>\u2009=\u20090.039).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>DWIBS is a valuable tool for monitoring treatment response and predicting outcome in patients with CRPC undergoing Ra-223 therapy. Early intervention or treatment modification is recommended for patients with DWIBS-PD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11604-025-01817-2","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:07:59Z","timestamp":1750118879000},"page":"1688-1695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of whole-body diffusion-weighted imaging with background body signal suppression in CRPC patients undergoing Ra-223 therapy: an exploratory analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-0272","authenticated-orcid":false,"given":"Yumiko","family":"Kono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nae","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1817_CR1","unstructured":"So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Canadian Urological Association journal = Journal de l\u2019Association des urologues du Canada. Published online 2012. https:\/\/www.semanticscholar.org\/paper\/Management-of-skeletal-related-events-in-patients-So-Chin\/d60ad76bfb9a750c683ee239b3b1fe5ab50b58d7. Accessed 19 Oct 2024."},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","volume":"44","author":"F Vignani","year":"2016","unstructured":"Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev. 2016;44:61\u201373. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.002.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1817_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.semnuclmed.2019.11.005","volume":"50","author":"AE Brito","year":"2020","unstructured":"Brito AE, Etchebehere E. Radium-223 as an approved modality for treatment of bone metastases. Semin Nucl Med. 2020;50(2):177\u201392. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.11.005.","journal-title":"Semin Nucl Med"},{"issue":"6_suppl","key":"1817_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/jco.2013.31.6_suppl.11","volume":"31","author":"NJ Vogelzang","year":"2013","unstructured":"Vogelzang NJ, Parker C, Nilsson S, Coleman RE, O\u2019Bryan-Tear CG, Shan M, et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). JCO. 2013;31(6_suppl):11\u201311. https:\/\/doi.org\/10.1200\/jco.2013.31.6_suppl.11.","journal-title":"JCO"},{"issue":"17","key":"1817_CR5","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3390\/cancers13174346","volume":"13","author":"K Van Der Zande","year":"2021","unstructured":"Van Der Zande K, Oyen WJG, Zwart W, Bergman AM. Radium-223 treatment of patients with metastatic castration resistant prostate cancer: biomarkers for stratification and response evaluation. Cancers. 2021;13(17):4346. https:\/\/doi.org\/10.3390\/cancers13174346.","journal-title":"Cancers"},{"issue":"7","key":"1817_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134133","volume":"10","author":"HB Jee","year":"2015","unstructured":"Jee HB, Park MJ, Lee HS, Park MS, Kim MJ, Chung YE. Is Non-contrast CT adequate for the evaluation of hepatic metastasis in patients who cannot receive iodinated contrast media? PLoS ONE. 2015;10(7): e0134133. https:\/\/doi.org\/10.1371\/journal.pone.0134133.","journal-title":"PLoS ONE"},{"issue":"9","key":"1817_CR7","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00330-008-0968-z","volume":"18","author":"TC Kwee","year":"2008","unstructured":"Kwee TC, Takahara T, Ochiai R, Nievelstein RAJ, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18(9):1937\u201352. https:\/\/doi.org\/10.1007\/s00330-008-0968-z.","journal-title":"Eur Radiol"},{"key":"1817_CR8","unstructured":"Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Cauteren MV. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiation medicine. Published online July 1, 2004. https:\/\/www.semanticscholar.org\/paper\/Diffusion-weighted-whole-body-imaging-with-body-and-Takahara-Imai\/7772ce8c1fff127198a138e9dabf1276b7fb4d2c. Accessed 20 Oct 2024."},{"issue":"6","key":"1817_CR9","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2214\/AJR.06.1403","volume":"188","author":"DM Koh","year":"2007","unstructured":"Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188(6):1622\u201335. https:\/\/doi.org\/10.2214\/AJR.06.1403.","journal-title":"Am J Roentgenol"},{"issue":"5","key":"1817_CR10","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","volume":"28","author":"O Sartor","year":"2017","unstructured":"Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx044.","journal-title":"Ann Oncol"},{"issue":"5","key":"1817_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/0300891619851376","volume":"105","author":"R Gallicchio","year":"2019","unstructured":"Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, et al. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. Tumori. 2019;105(5):367\u201377. https:\/\/doi.org\/10.1177\/0300891619851376.","journal-title":"Tumori"},{"issue":"3","key":"1817_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/21681805.2014.982169","volume":"49","author":"R Nome","year":"2015","unstructured":"Nome R, Hernes E, Bogsrud TV, Bj\u00f8ro T, Foss\u00e5 SD. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol. 2015;49(3):211\u20137. https:\/\/doi.org\/10.3109\/21681805.2014.982169.","journal-title":"Scand J Urol"},{"issue":"1","key":"1817_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.22038\/aojnmb.2017.9896","volume":"6","author":"K Maruyama","year":"2018","unstructured":"Maruyama K, Utsunomia K, Nakamoto T, Kawakita S, Murota T, Tanigawa N. Utility of F-18 FDG PET\/CT for detection of bone marrow metastases in prostate cancer patients treated with radium-223. Asia Ocean J Nucl Med Biol. 2018;6(1):61\u20137. https:\/\/doi.org\/10.22038\/aojnmb.2017.9896.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"2","key":"1817_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2214\/AJR.19.21656","volume":"214","author":"W Sun","year":"2020","unstructured":"Sun W, Li M, Gu Y, Sun Z, Qiu Z, Zhou Y. Diagnostic value of whole-body DWI with background body suppression plus calculation of apparent diffusion coefficient at 3 T versus 18F-FDG PET\/CT for detection of bone metastases. Am J Roentgenol. 2020;214(2):446\u201354. https:\/\/doi.org\/10.2214\/AJR.19.21656.","journal-title":"Am J Roentgenol"},{"issue":"2","key":"1817_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/cancers17020275","volume":"17","author":"M Parillo","year":"2025","unstructured":"Parillo M, Mallio CA. The whole-body MRI reporting and data system guidelines for prostate cancer (MET-RADS-P), multiple myeloma (MY-RADS), and cancer screening (ONCO-RADS). Cancers. 2025;17(2):275. https:\/\/doi.org\/10.3390\/cancers17020275.","journal-title":"Cancers"},{"issue":"4","key":"1817_CR16","doi-asserted-by":"publisher","first-page":"e0153840","DOI":"10.1371\/journal.pone.0153840","volume":"11","author":"MD Blackledge","year":"2016","unstructured":"Blackledge MD, Tunariu N, Orton MR, Padhani AR, Collins DJ, Leach MO, et al. Inter- and intra-observer repeatability of quantitative whole-body, diffusion-weighted imaging (WBDWI) in metastatic bone disease. PLoS ONE. 2016;11(4):e0153840. https:\/\/doi.org\/10.1371\/journal.pone.0153840.","journal-title":"PLoS ONE"},{"issue":"1","key":"1817_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2016160646","volume":"283","author":"R Perez-Lopez","year":"2017","unstructured":"Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, et al. Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology. 2017;283(1):168\u201377. https:\/\/doi.org\/10.1148\/radiol.2016160646.","journal-title":"Radiology"},{"issue":"4","key":"1817_CR18","doi-asserted-by":"publisher","first-page":"e91779","DOI":"10.1371\/journal.pone.0091779","volume":"9","author":"MD Blackledge","year":"2014","unstructured":"Blackledge MD, Collins DJ, Tunariu N, Orton MR, Padhani AR, Leach MO, et al. Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS ONE. 2014;9(4):e91779. https:\/\/doi.org\/10.1371\/journal.pone.0091779.","journal-title":"PLoS ONE"},{"issue":"5","key":"1817_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-022-06082-3","volume":"50","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 therapy in prostate cancer using bone scan index (J-RAP-BSI) trial. Eur J Nucl Med Mol Imag. 2023;50(5):1487\u201398. https:\/\/doi.org\/10.1007\/s00259-022-06082-3.","journal-title":"Eur J Nucl Med Mol Imag"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01817-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:53:07Z","timestamp":1759146787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01817-2","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}